About ECRON AcuNova   Vision and Quality policy   Letter from Leaders      Letter from Vice Chairman      Letter from President   The Team   Fact sheet     LETTER FROM THE VICE CHAIRMAN     India has attracted several clinical research projects in the last 5 years seeking quality data and speedy completion. Sites meeting ICH-GCP guidelines, English speaking investigators and drug naïve patients have enabled India to emerge as a key global destination for clinical research.   ECRON AcuNova has been entrusted with key trials involving recombinant drugs, monoclonal antibodies and diagnostic agents. Global regulation has accepted the research data produced by us and accorded approval to sponsors. Sponsors have found supply chain management and Central Lab service by us particularly useful in project management.   While we have served a wide spectrum of studies, our reputation has been particularly high in phase II trials for bio pharma and phase II-III trials for diagnostics and device companies. Many sponsors have opted for comprehensive services including CDM and Bio Statistics.   We are encouraged by your response and have now opted to expand our forte in the European and US market with our merger with ECRON GmbH, who brings on board 20 years of enriched experience in successfully bringing drugs into the market. Today we have with us human capital of over 265 professionals and are adding services like Bio Imaging and cardiac safety analysis which are becoming a mandate by leading regulators.   We look forward to beginning as a new entity and compel you to look at the uniqueness of our new relationship and embark on our journey with this new entity. We welcome you to partner with us in bringing new drugs, therapies and devices to market with innovation and speed..   D A Prasanna Vice Chairman & Managing Director Manipal AcuNova Ltd T: 91 80 6691 5701 da.prasanna@ecronacunova.com   > next

Privacy Policy     Disclaimer